Novavax (NVAX) Operating Expenses: 2009-2025
Historic Operating Expenses for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to $248.5 million.
- Novavax's Operating Expenses rose 13.70% to $248.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $757.2 million, marking a year-over-year decrease of 36.19%. This contributed to the annual value of $931.1 million for FY2024, which is 39.94% down from last year.
- According to the latest figures from Q3 2025, Novavax's Operating Expenses is $248.5 million, which was up 79.82% from $138.2 million recorded in Q2 2025.
- In the past 5 years, Novavax's Operating Expenses registered a high of $1.0 billion during Q4 2021, and its lowest value of $138.2 million during Q2 2025.
- In the last 3 years, Novavax's Operating Expenses had a median value of $248.5 million in 2025 and averaged $274.5 million.
- As far as peak fluctuations go, Novavax's Operating Expenses surged by 2,396.24% in 2021, and later plummeted by 63.72% in 2023.
- Quarterly analysis of 5 years shows Novavax's Operating Expenses stood at $1.0 billion in 2021, then tumbled by 42.58% to $601.3 million in 2022, then fell by 21.02% to $474.9 million in 2023, then plummeted by 53.80% to $219.4 million in 2024, then rose by 13.70% to $248.5 million in 2025.
- Its Operating Expenses stands at $248.5 million for Q3 2025, versus $138.2 million for Q2 2025 and $151.1 million for Q1 2025.